Press Releases

Company News
View Summary Breast Cancer Research and Treatment Publishes Oncotype DX® DCIS Score™ Study
Jul 14, 2015
PDF 36.8 KB
View Summary Journal of Surgical Oncology Publishes Study Showing Oncotype DX® DCIS Score™ Result Changes Treatment Recommendations in 30 Percent of DCIS Breast Cancer Patients
Jun 23, 2015
PDF 37.9 KB
View Summary Genomic Health Presents Positive Proof-of-Concept Data for Bladder Cancer Liquid Biopsy Test
Jun 16, 2015
PDF 34.5 KB
View Summary Genomic Health to Present Proof-of-Concept Bladder Cancer Liquid Biopsy Data at AACR Precision Medicine Meeting
Jun 11, 2015
PDF 52.7 KB
View Summary Oncotype DX® Presentations at ASCO in Breast and Prostate Cancer Reinforce Genomic Health's Leadership in Optimizing Cancer Treatment
Jun 1, 2015
PDF 56.0 KB
View Summary Multiple Oncotype DX® Presentations at the American Society of Clinical Oncology Annual Meeting Highlight Genomic Health's Leadership in Personalizing Breast, Prostate Cancer Care
May 27, 2015
PDF 37.9 KB
View Summary Genomic Health to Present at the Jefferies 2015 Global Healthcare Conference
May 27, 2015
PDF 34.7 KB
View Summary Genomic Health Announces Favorable Draft Local Coverage Determination from Palmetto GBA® on Medicare Coverage for the Oncotype DX® Prostate Cancer Test
May 21, 2015
PDF 36.6 KB
View Summary UCSF-led Study Shows Oncotype DX® and MRI May Provide Independent Information in Favorable Risk Prostate Cancer
May 20, 2015
PDF 35.4 KB
View Summary Genomic Health Advances Liquid Biopsy Pipeline, Shows Ability to Accurately Monitor Urine for Presence of Bladder Cancer
May 18, 2015
PDF 35.1 KB
View Summary Oncotype DX® Prostate Cancer Test Improves Risk Assessment for One in Four Men and Reduces Overall Healthcare Costs
May 15, 2015
PDF 37.4 KB
View Summary St. Gallen International Breast Cancer Guidelines for the Third Time Distinguish Oncotype DX® as the Only Multi-Gene Test Validated to Predict Chemotherapy Benefit
May 11, 2015
PDF 39.1 KB
View Summary Genomic Health to Present Multiple Oncotype DX® Studies and Positive Liquid Biopsy Results at American Urological Association Annual Meeting May 15-19
May 7, 2015
PDF 37.8 KB
View Summary Genomic Health to Present at the Bank of America Merrill Lynch 2015 Healthcare Conference
May 6, 2015
PDF 37.1 KB
View Summary Genomic Health Announces First Quarter 2015 Financial Results and Reports Record Oncotype DX® Test Volume
May 5, 2015
PDF 47.1 KB
View Summary Genomic Health Announces Publication of Oncotype DX® Prostate Cancer Test Decision Impact Study in Urology Practice, Supporting Wider Adoption and Reimbursement
Apr 30, 2015
PDF 36.2 KB
View Summary Genomic Health to Announce First Quarter 2015 Financial Results and Host Conference Call on Tuesday, May 5, 2015
Apr 28, 2015
PDF 36.2 KB
View Summary Multiple Data Presentations Demonstrate Positive Direct Patient Impact of Oncotype DX® Breast Cancer Test Globally
Mar 20, 2015
PDF 61.6 KB
View Summary Genomic Health Announces Year-End 2014 Financial Results, Provides 2015 Financial Outlook
Feb 10, 2015
PDF 50.6 KB
View Summary Following NICE's Exclusive Recommendation, NHS England Agrees to Access Program for Oncotype DX® Breast Cancer Test
Feb 5, 2015
PDF 38.4 KB
Showing 1-20 of 324 Page: 1 2 3 4 5 ... 17  Next 20


  • ASCO® is a registered trademark of the American Society of Clinical Oncology. ASCO does not endorse any product or therapy. ® is a registered trademark of the National Comprehensive Cancer Network. The NCCN does not endorse any product or therapy.

Contact Information

For Investors:
650.569.2281
investors@genomichealth.com

For Media:
650.569.2215
media@genomichealth.com

Email Alerts

To sign-up to receive email alerts for press releases, stock information, new calendar events and/or SEC filings click here.

Shareholder Tools



DISCLAIMER

The information in the fact sheet, press releases and webcasts should be considered accurate only as of the date of the document or presentation. We disclaim any obligation to supplement or update the information in these documents or presentations.

Forward-Looking Statements

This website contains forward-looking statements. Any statements contained in this website that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including risks and uncertainties associated with the reimbursement for and adoption of Oncotype DX; commercialization of any future tests; the nature and sources of our revenues; our dependence on collaborative relationships; the regulation of Oncotype DX or any future tests we may develop by the FDA; the attributes of our products; the benefits of personalized medicine and its ability to impact treatment decisions; the outcome and success of clinical trials; the applicability of clinical results to actual outcomes; the company's beliefs regarding the potential benefits that may be obtained from additional tests; and other factors detailed from time to time in Genomic Health's periodic filings with the Securities and Exchange Commission. Genomic Health, Inc. specifically disclaims any obligation to update any forward-looking statements.